Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 323

1.

[Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].

Millán J, Alegría E, Guijarro C, Lozano JV, Vitale GC, González-Timón B, González-Juanatey JR.

Med Clin (Barc). 2013 Nov 16;141(10):430-6. doi: 10.1016/j.medcli.2012.09.030. Epub 2012 Dec 12. Spanish.

PMID:
23246165
2.
3.

Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS).

Drexel H, Chazelle F, Fauer C, Lautsch D, Gitt AK.

Wien Klin Wochenschr. 2011 Oct;123(19-20):611-7. doi: 10.1007/s00508-011-0057-1. Epub 2011 Sep 29.

PMID:
21947362
4.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
5.

[Diabetic dyslipidaemia and the atherosclerosis].

Márk L, Dani G.

Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Review. Hungarian.

PMID:
27133274
6.

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.

Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ; DYSIS Investigators..

Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10.

PMID:
21450578
7.
8.

Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS).

da Silva PM, Cardoso SM; Investigadores do Estudo DYSIS Portugal..

Rev Port Cardiol. 2011 Jan;30(1):47-63. English, Portuguese.

9.

Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): results of the Dyslipidemia International Study (DYSIS).

Viigimaa M, Erglis A, Latkovskis G, Mäeots E, Petrulionienė Ž, Šlapikas R, Gocentiene A, Bramlage P, Brudi P.

Medicina (Kaunas). 2014;50(1):44-53. doi: 10.1016/j.medici.2014.05.003. Epub 2014 Jun 10.

10.

Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS).

Horgan S, Crowley J, Feely J, McAdam B, Shanahan E, Vaughan C.

Ir J Med Sci. 2011 Jun;180(2):343-9. doi: 10.1007/s11845-011-0702-8. Epub 2011 Mar 13.

PMID:
21400212
11.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

12.

Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS).

Raal FJ, Blom DJ, Naidoo S, Bramlage P, Brudi P.

Cardiovasc J Afr. 2013 Sep;24(8):330-8. doi: 10.5830/CVJA-2013-071.

13.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
14.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
15.

Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).

Wang F, Ye P, Hu D, Min Y, Zhao S, Wang Y, Mu Y, Yan X, Li Z, Wei Y, Li J; DYSIS-China Study Investigators..

Atherosclerosis. 2014 Nov;237(1):99-105. doi: 10.1016/j.atherosclerosis.2014.08.023. Epub 2014 Sep 1.

PMID:
25238215
16.

The lipid triad, or how to reduce residual cardiovascular risk?

Girard-Mauduit S.

Ann Endocrinol (Paris). 2010 Mar;71(2):89-94. doi: 10.1016/j.ando.2010.02.001. Epub 2010 Mar 19.

PMID:
20303470
17.

Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).

Zhao S, Wang Y, Mu Y, Yu B, Ye P, Yan X, Li Z, Wei Y, Ambegaonakr BM, Hu D; DYSIS-China Study Investigators..

Atherosclerosis. 2014 Aug;235(2):463-9. doi: 10.1016/j.atherosclerosis.2014.05.916. Epub 2014 Jun 5.

PMID:
24950001
18.

[How to treat dyslipidemia in patients with metabolic syndrome].

Soška V.

Vnitr Lek. 2015 Jul-Aug;61(7-8):721-4. Czech.

PMID:
26375703
19.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
20.

Persistent lipid abnormalities in statin-treated patients: Portuguese diabetic subpopulation of the Dyslipidaemia International Study (DYSIS).

Marques da Silva P, Massano Cardoso S, Ferreira AM; Portuguese DYSIS Study Investigators..

Prim Care Diabetes. 2015 Aug;9(4):283-9. doi: 10.1016/j.pcd.2014.09.002. Epub 2014 Nov 4.

PMID:
25449144

Supplemental Content

Support Center